Journal d'hépatologie et des troubles gastro-intestinaux
Libre accès

Abstrait

Hépatite C et son évolution chez les patients atteints d'une affection maligne recevant une chimiothérapie par rapport aux patients non malins

Dawood Banday, Ashaq Hussain Parrey, Bilal Rather

Introduction: Hepatitis C Virus (HCV) is an RNA virus that belongs to the family of flaviviruses. Chronic hepatitis C infection is a very common disease globally affecting over 180 million people. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and a primary indication for liver transplantation. As we move to the new era of oral antivirals as the treatment of hepatitis C we needed to see their efficacy and safety in patients with hepatitis C and underlying malignancy compared to the patients with hepatitis C without malignancy. Patients with malignancy with hepatitis C respond equally to the treatment of hepatitis C as patients without malignancy

Aims and objectives: The aim of the study was to find the outcome of treatment in patients with hepatitis C with malignancy receiving Chemotherapy in comparison to non-malignant patients with hepatitis C with oral versus parenteral antiviral.

Results: Out of 80 patients 38 patients which were confirmed HCV positive had malignancy and were on chemotherapy protocol were studied and compared with 42 patients of HCV positive without any malignancies. Initial response to treatment in malignant cohort was blunted (60.5% malignant patients with high viral load (p=<0.001) after 12 weeks), which later improved over treatment duration. Treatment complications were more common in malignant cohort as expected. Response was equivalent in IFN α versus Protease inhibitor sofosbuvir group.

Conclusion: Patients with malignancy on chemotherapy fared not inferior to patients without malignancies on HCV treatment.